Nivolumab plus ipilimumab improved long-term survival in patients with advanced melanoma
1. The 6.5-year progression-free survival for the nivolumab combination group, nivolumab group and in the ipilimumab group were 34%, 29% ...
Tag: advanced melanoma
Evening-dose immune checkpoint inhibitors were associated with worse survival outcomes
1. Receiving at least 20% of infusions after 1630h was associated with decreased overall survival in patients treated with immune-checkpoint ...
#VisualAbstract: High-dose glucocorticoids may be detrimental for the management of patients with advanced melanoma expieriencing immune-related adverse events
Click to read the study in Clinical Cancer Research.
#VisualAbstract: Presence of anti-telomerase CD4+ Th1 immunity is associated with better outcomes in patients with melanoma
Click to read the study in the Journal of Investigative Dermatology.
#VisualAbstract: Melanoma survival outcomes have improved between 2003 and 2019 amidst increasing incidence rates
Click to read the study in the European Journal of Cancer.
#VisualAbstract: Greater immunosuppression is associated with worse outcomes in patients with advanced melanoma receiving ipilimumab and anti-PD-1 therapy
Click to read the study in the European Journal of Cancer.
#VisualAbstract: Encorafenib plus binimetinib improves quality of life outcomes compared to vemurafenib in patients with advanced BRAF-mutated melanoma
Click to read the study in the European Journal of Cancer.
#VisualAbstract: Local therapy is effective for the treatment of solitary melanoma progression
Click to read the study in the European Journal of Cancer.
#VisualAbstract: Ipilimumab plus anti-PD-1 therapy is effective in patients with anti-PD-L1 resistant metastatic melanoma
Click to read the study in The Lancet Oncology.
#VisualAbstract: Prolgolimab is efficacious and tolerable in patients with advanced melanoma
Click to read the study in the European Journal of Cancer.